As proof-of-principle, a recent clinical study of apelin in PAH showed that administration of apelin provided significant additive benefit, on top of concomitant PDE5 inhibitor therapy, in decreasing pulmonary vascular resistance, and increasing cardiac output and stroke volume (Brash et al., 2018). The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.